CD133 is expressed on immature hematopoietic stem and progenitor cells but is not found on mature blood cells. In contrast to the CD34 antigen, CD133 is not expressed by late progenitors such as pre-B cells, CFU-E, and CFU-G. The stem cell marker CD133 was formerly known as AC133.
The CliniMACS
®
CD133 Product Line consists of murine anti-CD133 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non‑pyrogenic solution.
The performance of the CliniMACS CD133 Product Line depends on the individual separation strategy. For

Data and images for
CliniMACS
®
CD133 Product Line

Figures

Figure 1

Flow cytometric analysis of CD133–enriched cells from a mobilized leukapheresis product using the CliniMACS CD133 System.
Before enrichment
After enrichment
View details

Figure 1

Flow cytometric analysis of CD133–enriched cells from a mobilized leukapheresis product using the CliniMACS CD133 System.
View details

Figure 1

Flow cytometric analysis of CD133–enriched cells from a mobilized leukapheresis product using the CliniMACS CD133 System.

Figure 2

Flow cytometric analysis of CD133–enriched stem cells from a bone marrow aspirate using the CliniMACS CD133 System.
A:
B:
Before enrichment
After enrichment
View details

Figure 2

Flow cytometric analysis of CD133–enriched stem cells from a bone marrow aspirate using the CliniMACS CD133 System.
View details

Figure 2

Flow cytometric analysis of CD133–enriched stem cells from a bone marrow aspirate using the CliniMACS CD133 System.

Specifications for
CliniMACS
®
CD133 Product Line

Overview

CD133 is expressed on immature hematopoietic stem and progenitor cells but is not found on mature blood cells. In contrast to the CD34 antigen, CD133 is not expressed by late progenitors such as pre-B cells, CFU-E, and CFU-G. The stem cell marker CD133 was formerly known as AC133.
The CliniMACS
®
CD133 Product Line consists of murine anti-CD133 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non‑pyrogenic solution.
The performance of the CliniMACS CD133 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.

Detailed product information

Applications

The CliniMACS CD133 Product Line was developed for the enrichment of CD133
+
cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.

Referenced literature

CD133
+
stem cells are investigated in various areas of regenerative medicine, such as cardiovascular diseases, liver diseases and peripheral artery diseases.
1–9
Besides the interest in non-hematopoietic applications, CD133
+
stem cell enrichment is performed to provide an allogeneic stemcell graft highly purified for CD133
+
cells and depleted of unwanted cells.
10–15
In autologous transplantation, CD133
+
progenitor cells can be enriched in order to passively remove tumor cells from the graft (purging).
16

Disclaimer

The CliniMACS
®
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for
in vitro
use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS GMP MicroBeads are for research use and
ex vivo
cell processing only.
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use.

Resources for
CliniMACS
®
CD133 Product Line

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for
CliniMACS
®
CD133 Product Line

Publications

  1. Stamm, C. et al. (2003) Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 4, 361(9351): 45-46
  2. Stamm, C. et al. (2007)
    Intramyocardial delivery of CD133
    +
    bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies.
    J. Thorac. Cardiovasc. Surg. 133: 717-725
  3. Klein (2007) Eur. Cardiovasc. Dis. 1: 123-125
  4. Klein, H. M. et al. (2007)
    Intramyocardial implantation of CD133
    +
    stem cells improved cardiac function without bypass surgery.
    Heart Surg. Forum 10: E66-69
  5. Bartunek et al. (2005) Circulation 30: 178-183
  6. Clinical Trials.gov : NCT00950274
  7. am Esch, J. S. 2nd et al. (2005)
    Portal application of autologous CD133
    +
    bone marrow cells to the liver: a novel concept to support hepatic regeneration.
    Stem Cells 23(4): 463-470
  8. Fürst, G. et al. (2007)
    Portal vein embolization and autologous CD133
    +
    bone marrow stem cells for liver regeneration: initial experience.
    J. Immunother. 243(1): 171-179
  9. Cañizo et al. (2007)
    Peripheral endothelial progenitor cells (CD133
    +
    ) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up.
    Cytotherapy 9(1): 99-102
  10. Bitan et al. (2005)
    Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133
    +
    -purified stem cells.
    Exp. Hematol. 33: 713-718
  11. Bornhäuser, M. et al. (2005)
    Rapid reconstitution of dendritic cells after allogeneic transplantation of CD133
    +
    selected hematopoietic stem cells.
    Leukemia 19: 161-165
  12. Peled et al. (2004)
    Pre-clinical development of cord blood-derived progenitor cell graft expanded
    ex vivo
    with cytokines and the polyamine copper chelator tetraethylenepentamine.
    Cytotherapy 6: 344-355
  13. Lang et al. (2004)
    Transplantation of a combination of CD133
    +
    and CD34
    +
    selected progenitor cells from alternative donors.
    Br J Haematol 124: 72-79
  14. Lang et al. (2004) Correction of persistent thrombocytopenia by a boost of CD133+ selected stem cells in a patient transplanted for Wiskott-Aldrich syndrome 10 years ago. Bone Marrow Transplant. 33(1): 879-880
  15. Gordon et al. (2003)
    Large-scale isolation of CD133
    +
    progenitor cells from G-CSF mobilized peripheral blood stem cells.
    Bone Marrow Transplant. 31: 17-22
  16. Koehl et al. (2002) Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia. Bone Marrow Transplant. 29: 927-930